Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kaoru Kubota"'
Autor:
Kaoru Kubota, Yuichiro Ohe, Hidetoshi Hayashi, Tomohide Tamura, Tsuneo Shimokawa, Makoto Nishio, Toyoaki Hida, Tomohisa Baba, Kazutaka Miyadera, Kazuo Kasahara, Haruyasu Murakami, Hiroshi Sakai, Fumio Imamura, Yukio Hosomi
Publikováno v:
Investigational New Drugs
Summary Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients wit
Autor:
Norihiko Ikeda, Toshiaki Saeki, Fumiyoshi Ohyanagi, Tomohide Tamura, Yutaka Tokuda, Kenichi Inoue, Hiroshi Sakai, Hiroshi Kagamu, Kaoru Kubota, Koichi Minato, Akihiko Osaki, Kazuhiko Yamada
Publikováno v:
Japanese Journal of Clinical Oncology. 49:121-129
Objective Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dos
Autor:
Sergey Orlov, Kaoru Kubota, Jesús Cárdenas Sánchez, Jin-Hyoung Kang, Li Zhang, Alexander N. Fleishman, Joseph K. Park, Vera Hirsh, Konstantinos N. Syrigos, Carlos H. Barrios, Gary Thomas, David H. Henry, Cisio De Oliveira Brandao, Tilman Steinmetz, Dianne Tomita, Pere Gascón, Martin Šmakal, Rajnish Nagarkar, David Gordon
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(2)
This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling.Adults with stage IV NSCLC expected to r
Autor:
Scott J, Antonia, Augusto, Villegas, Davey, Daniel, David, Vicente, Shuji, Murakami, Rina, Hui, Takayasu, Kurata, Alberto, Chiappori, Ki H, Lee, Maike, de Wit, Byoung C, Cho, Maryam, Bourhaba, Xavier, Quantin, Takaaki, Tokito, Tarek, Mekhail, David, Planchard, Young-Chul, Kim, Christos S, Karapetis, Sandrine, Hiret, Gyula, Ostoros, Kaoru, Kubota, Jhanelle E, Gray, Luis, Paz-Ares, Javier, de Castro Carpeño, Corinne, Faivre-Finn, Martin, Reck, Johan, Vansteenkiste, David R, Spigel, Catherine, Wadsworth, Giovanni, Melillo, Maria, Taboada, Phillip A, Dennis, Mustafa, Özgüroğlu, Nguyen Kim, Luu
Publikováno v:
The New England Journal of Medicine, 379, 24, pp. 2342-2350
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (24), pp.2342-2350. ⟨10.1056/NEJMoa1809697⟩
The New England Journal of Medicine, 379, 2342-2350
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (24), pp.2342-2350. ⟨10.1056/NEJMoa1809697⟩
The New England Journal of Medicine, 379, 2342-2350
BACKGROUND: An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have
Autor:
Makoto Nishio, Diego Cortinovis, Lukas Makris, Giorgio V. Scagliotti, Domenico Galetta, Fabio Benedetti, Kaoru Kubota, Miyako Satouchi, G. Valmadre, Akira Inoue, Eiji Yoshihara, Seiji Niho
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 100
Objectives TAS-102 is an oral combination treatment comprised of an antimetabolite, trifluridine, a thymidine-based nucleoside analog, and tipiracil hydrochloride, at a molar ratio of 1:0.5. This antimetabolite has demonstrated efficacy in clinical t
Autor:
Yuji Minegishi, Yukiko Miura, Masahiro Seike, Kunugi Shinobu, Kaoru Kubota, Akihiko Miyanaga, Susumu Takeuchi, Yoshinobu Saito, Hideaki Mizutani, Kenichiro Atsumi, Rintaro Noro, Akihiko Gemma
Publikováno v:
Japanese journal of clinical oncology. 46(7)
Objective Amrubicin, which is used as a chemotherapeutic agent for lung cancer, can induce interstitial lung disease. There is insufficient evidence on the incidence of amrubicin-associated interstitial lung disease under practical use settings. We t
Autor:
Kaoru Kubota, Rintaro Noro, Chie Soeno, Mika Chiba, Masaru Matsumoto, Nobuhiko Nishijima, Masahiro Seike, Teppei Sugano, Akihiko Miyanaga, Akihiko Gemma
Publikováno v:
International Journal of Oncology
Nintedanib (BIBF1120) is a multi-targeted angiokinase inhibitor and has been evaluated in idiopathic pulmonary fibrosis and advanced non-small cell lung cancer (NSCLC) patients in clinical studies. In the present study, we evaluated the antitumor eff